Clear All
773 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Estrogens, Esterified Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est 2.5 mg Hormonal Therapy Estrogen Yes 1977 In Use
NA Fedratinib Hydrochloride Inrebic 100mg Chemotherapy Enzyme Inhibitor JAK2, FLT3 Yes 2019 In Use
NA Letrozole Femara 2.5 mg Hormonal Therapy Aromatase Inhibitor Yes 1997 In Use
J8610 Methotrexate Trexall 2.5 mg Chemotherapy Antimetabolite Folic Acid Analog Yes 1953 Jan 1, 1995 In Use
J9314 Pemetrexed (Teva) Pemetrexed (Teva) 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2022 Dec 21, 2022 In Use
Q5116 Trastuzumab-qyyp Trazimera 10mg Immunotherapy Monoclonal Antibody HER2 No 2020 Oct 1, 2019 In Use
NA Palbociclib Ibrance 100 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2015 In Use
J9219 Leuprolide Acetate Implant Viadur 65 mg Hormonal Therapy GnRH Agonist No 2000 Jan 1, 2016 In Use
NA Selpercatinib Retevmo 40mg, 80mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2020 In Use
S9338 Immunotherapy - non specific Home infusion therapy, immunotherapy NA Immunotherapy No Jan 1, 2002 In Use
J9011 Datopotamab Deruxtecan Datroway 1mg Immunotherapy Drug Antibody Conjugate Topoisomerase I, TROP2 No 2025 Sep 8, 2025 In Use
Q2041 Axicabtagene Ciloleucel Yescarta Up to 200 million Immunotherapy CAR-T CD19 No 2017 Jan 1, 2019 In Use
Q5160 Bevacizumab-nwgd (Jobevne) Jobevne 10mg Immunotherapy Monoclonal Antibody VEGFR No 2025 Jan 1, 2026 In Use
NA Dutasteride Avodart 0.5mg Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Yes 2002 In Use
NA Neratinib Nerlynx 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2017 In Use
J0207 Amifostine Ethyol 500 mg Ancillary Therapy Chemoprotective Detoxifying Agent No 1995 Jan 1, 1998 In Use
J8611 Methotrexate (jylamvo) Jylamvo 2.5mg Chemotherapy Antimetabolite Folic Acid Analog Yes 2023 Jun 10, 2024 In Use
J9030 Bacillus calmette-guerin BCG Vaccine, Tice BCG 1mg Immunotherapy Biological Response Modifier Live Vaccine No 1990 Jul 1, 2019 In Use
Q5101 Filgrastim Neupogen, Zarxio 1 mcg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 1991 Jul 1, 2015 In Use
NA Estramustine Phosphate Sodium Emcyt 140 mg Chemotherapy Alkylating Agent Nitrogen Mustard Yes 1981 In Use
J9173 Durvalumab Imfinzi 10mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2017 Jan 1, 2019 In Use
J9298 Nivolumab & Relatlimab-rmbw Opdualag 3mg/1mg Immunotherapy Checkpoint Inhibitor, Monoclonal Antibody PD-1, LAG3 No 2022 Sep 27, 2022 In Use
J9017 Arsenic Trioxide Trisenox 1 mg Chemotherapy Miscellaneous Agent PML/RARa No 2000 Jan 1, 2002 In Use
S0172 Chlorambucil Leukeran 2 mg Chemotherapy Alkylating Agent Nitrogen Mustard Yes 1957 Jan 1, 2002 In Use
J9056 Bendamustine hydrochloride (Vivimusta) Vivimusta 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2022 Jul 11, 2023 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.